コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ncoding production of the antibiotic and the beta-lactamase inhibitor.
2 dependent upon or enhanced by clavulanate, a beta-lactamase inhibitor.
3 the co-administration of an antibiotic and a beta-lactamase inhibitor.
4 nactivated with tazobactam, a potent class A beta-lactamase inhibitor.
5 mechanism distinct from that of traditional beta-lactamase inhibitors.
6 present one of the most promising classes of beta-lactamase inhibitors.
7 t)/k(inact) values of 2000, 1500, and 75 for beta-lactamase inhibitors.
8 e that exhibits resistance to most available beta-lactamase inhibitors.
9 ch is a unique mechanism of inhibition among beta-lactamase inhibitors.
10 with carbapenemase activity are resistant to beta-lactamase inhibitors.
11 ities and challenges to the search for novel beta-lactamase inhibitors.
12 terial siderophore, LN-1-255 is unique among beta-lactamase inhibitors.
13 m cephalosporins or to avoid inactivation by beta-lactamase inhibitors.
14 e rational design of mechanism-based class A beta-lactamase inhibitors.
15 ey show promise as leads to specific class D beta-lactamase inhibitors.
16 t bacteria and escape the action of existing beta-lactamase inhibitors.
17 have been prepared as a potential source of beta-lactamase inhibitors.
18 lactam antibiotics in a manner distinct from beta-lactamase inhibitors.
19 an intriguing new platform for the design of beta-lactamase inhibitors.
20 n aid the design of improved mechanism-based beta-lactamase inhibitors.
21 nd have implications for the design of novel beta-lactamase inhibitors.
22 nity of the active site for beta-lactams and beta-lactamase inhibitors.
23 , we evaluated the diagnostic utility of the beta-lactamase inhibitors 48-1220 (Ro 48-1220) and LN-2-
24 the benzhydryl ester of the mechanism-based beta-lactamase inhibitor, 7-[(2'-pyridyl)methylidene]-ce
27 provide insights for the development of new beta-lactamase inhibitors against these critical drug re
28 These approaches include the development of beta-lactamase inhibitors and compounds that interfere w
29 lization has generated a renewed interest in beta-lactamase inhibitors and improved the prospects for
31 , and combinations of penicillins, including beta-lactamase inhibitors) and two had a known interacti
32 d, evaluated as serine (classes A, C, and D) beta-lactamase inhibitors, and compared with respect to
33 including green fluorescent proteins (GFPs), beta-lactamase inhibitors, and nuclear receptors, and we
34 lass, such as meropenem, with clavulanate, a beta-lactamase inhibitor, are being evaluated for the tr
35 with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem
36 c inhibitors, such as the derivatives of the beta-lactamase inhibitor avibactam, are closer to the cl
38 reacylation complex of sulbactam, a clinical beta-lactamase inhibitor, bound in the active site of th
39 ituation now dictates that second-generation beta-lactamase inhibitors capable of encompassing both c
40 of Mycobacterium tuberculosis (Mtb) with the beta-lactamase inhibitor clavulanate together with merop
43 o most cephalosporins, beta-lactams, and the beta-lactamase inhibitor clavulanic acid as well as resi
47 130 confer resistance to inactivation by the beta-lactamase inhibitors, clavulanic acid, and tazobact
50 e), a monocyclic beta-lactam (BAL30072), the beta-lactamase inhibitor combination of tazobactam with
51 nce to ampicillin/clavulanate, a beta-lactam/beta-lactamase inhibitor combination used to treat serio
52 an emerging threat to the use of beta-lactam/beta-lactamase inhibitor combinations (e.g. amoxicillin/
54 ies suggested that resistance to beta-lactam-beta-lactamase inhibitor combinations conferred by pLRM7
55 ndings should not be extended to beta-lactam/beta-lactamase inhibitor combinations in development, as
56 nded-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations is achievable via
57 y with respect to empirical therapy with new beta-lactamase inhibitor combinations such as ceftazidim
61 initiated to discover a new series of serine beta-lactamase inhibitors containing a boronic acid phar
62 that a combination of L,D-transpeptidase and beta-lactamase inhibitors could effectively target persi
63 fective against the TEM and P99 enzymes; the beta-lactamase inhibitors currently employed in medical
67 has important implications in the design of beta-lactamase inhibitors for drug resistant variants li
68 tive drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstre
69 tion of extended-spectrum cephalosporins and beta-lactamase inhibitors has driven the evolution of ex
72 ere to guide the creation of two novel short beta-lactamase inhibitors, here named dBLIP-1 and -2, wi
73 more susceptible to inactivation by sulfone beta-lactamase inhibitors (i.e., sulbactam and tazobacta
74 and avibactam are clinically deployed serine beta-lactamase inhibitors, important as a defence agains
76 ms, whereas newer drug classes include novel beta-lactamase inhibitors in combination with new or app
77 resistant to combinations of beta-lactam and beta-lactamase inhibitors is creating great difficulties
80 f inhibition of these enzymes by therapeutic beta-lactamase inhibitors is probed using a novel approa
81 rd clavulanic acid, the clinically important beta-lactamase inhibitor, is catalyzed by the thiamin di
83 d in the final deprotection/isolation of the beta-lactamase inhibitor MK-7655 as a part of its manufa
84 ephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains a
86 the monobactam aztreonam and BAL29880, a new beta-lactamase inhibitor of the monobactam class, inacti
87 ztreonam-like beta-lactams plus nonclassical beta-lactamase inhibitors, particularly avibactam-like a
92 lactam agents including agents paired with a beta-lactamase inhibitor (r >/= 0.87) and for ciprofloxa
93 determine the molecular factors that lead to beta-lactamase inhibitor resistance for the M69V variant
94 CI, 1.15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.2
95 lved phenotypic tests, isoelectric focusing, beta-lactamase inhibitor studies, spectrophotometric ass
96 rial response to the clinical use of class A beta-lactamase inhibitors such as tazobactam and clavula
97 he high resolution crystal structures of the beta-lactamase inhibitors sulbactam and clavulanic acid
99 he enzyme's inhibition by three FDA-approved beta-lactamase inhibitors: sulbactam, tazobactam, and cl
100 antibacterial combination consisting of the beta-lactamase inhibitor tazobactam and a fourth-generat
102 to guide derivatization of a lead series of beta-lactamase inhibitors that had heretofore resisted o
103 characterization of expanded-spectrum serine beta-lactamase inhibitors that potently inhibit clinical
104 coproduction of beta-lactam antibiotics and beta-lactamase inhibitors, the coproduction of type A an
105 despread clinical use as part of beta-lactam beta-lactamase inhibitor therapy directed against penici
106 is generating an interest in developing new beta-lactamase inhibitors to complement currently availa
107 ts, including penicillins, cephalosporins, a beta-lactamase inhibitor, vancomycin, erythromycin, tetr
108 aining 10 beta-lactam drugs with and without beta-lactamase inhibitors was developed to identify beta
110 an effort to identify non-beta-lactam-based beta-lactamase inhibitors, we used the crystallographic
112 se, and tazobactam, a commercially available beta-lactamase inhibitor, were rapidly mixed on the mill
113 ombination of a beta-lactam antibiotic and a beta-lactamase inhibitor, which, on the basis of the mic
116 methoxazole-trimethoprim, or beta-lactam and beta-lactamase inhibitor with or without a macrolide) ha
117 activities of sulbactam and two novel penem beta-lactamase inhibitors with sp2 hybridized C3 carboxy
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。